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ABSTRACT Although the lipid mediator prostaglan-
din E2 (PGE2) exerts antifibrotic effects by inhibiting
multiple fibroblast functions, its ability to regulate
fibroblast survival is unknown. Here, we examined the
effects of this prostanoid on apoptosis and apoptosis
pathways in normal and fibrotic lung fibroblasts. As
compared to medium alone, 24 h of treatment with
PGE2 increased apoptosis of normal lung fibroblasts in
a dose-dependent manner (EC5050 nM), as measured
by annexin V staining, caspase 3 activity, cleavage of
poly-ADP-ribose polymerase, and single-stranded DNA
levels. PGE2 also potentiated apoptosis elicited by Fas
ligand plus cycloheximide. These proapoptotic actions
were dependent on signaling through the EP2/EP4
receptors and by downstream activation of both
caspases 8 and 9. Silencing and gene deletion of PTEN
demonstrated that the effects of PGE2 involved de-
creased activity of the prosurvival molecule Akt. PGE2
also down-regulated expression of survivin, an inhibitor
of apoptosis, and increased expression of Fas. Fibro-
blasts from patients with pulmonary fibrosis exhibited
resistance to the apoptotic effects of PGE2. These
findings show for the first time that, in contrast to its
effects on many other cell types, PGE2 promotes apo-
ptosis in lung fibroblasts through diverse pathways.
They provide another dimension by which PGE2 may
inhibit, and perhaps even reverse, fibrogenesis in pa-
tients with interstitial lung disease.—Huang, S. K.,
White, E. S., Wettlaufer, S. H., Grifka, H., Hogaboam,
C. M., Thannickal, V. J., Horowitz, J. C., Peters-Golden,
M. Prostaglandin E2 induces fibroblast apoptosis by
modulating multiple survival pathways. FASEB J. 23,
4317–4326 (2009). www.fasebj.org
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A proper balance between cell survival and death is
critical for maintaining normal tissue homeostasis, and
many diseases are characterized by a disruption in this
balance (1). For example, both excess epithelial cell
apoptosis (2–4) and enhanced fibroblast survival (5–8)
are believed to be central to the pathogenesis of
pulmonary fibrotic disorders. While fibroblasts are crit-
ical to normal wound healing, their apoptosis is ulti-
mately necessary to prevent excessive matrix deposition
and scarring (9). Fibroblasts from patients with pulmo-
nary fibrosis have been shown to exhibit resistance to
apoptosis (10, 11). Thus, identifying mediators that
modulate fibroblast survival may not only shed light on
disease pathogenesis, but also provide targets for the
development of novel therapies that may limit or even
reverse the progression of this deadly disease. Although
one approach is to interrupt the actions of mediators
that promote fibroblast survival, such as transforming
growth factor (TGF)-, another approach is to aug-
ment pathways that promote fibroblast apoptosis.
Prostaglandin E2 (PGE2) is an antifibrotic lipid me-
diator derived from the metabolism of arachidonic acid
by cyclooxygenase. Human idiopathic pulmonary fibro-
sis (IPF) has been shown to be characterized by a
relative deficiency of PGE2 production (12–14) and
responsiveness (15, 16), and the latter has also been
observed in animal models of lung fibrosis (13). Elab-
orated from lung epithelial cells (17), fibroblasts (14),
and macrophages (18, 19), PGE2 inhibits fibroblast
proliferation (18, 19), collagen synthesis (20), migra-
tion (21, 22), and differentiation into myofibroblasts
(23). However, PGE2 has also been shown to be a
potent antiapoptotic/prosurvival mediator in normal
epithelial cells (24, 25), cancer cells (26, 27), T cells
(28, 29), and adipocytes (30). Whether PGE2 is also
antiapoptotic in normal lung fibroblasts, or instead
promotes apoptosis, which would be consistent with its
other antifibrotic actions, is unknown.
The purpose of our study was to delineate the effects
of PGE2 on lung fibroblast survival and the intracellular
mechanisms that mediate them. Our results show for
the first time that PGE2 promotes fibroblast apoptosis
through activation of multiple apoptotic pathways. This
is dependent on signaling through the E prostanoid
(EP) 2 and 4 receptors and activation of phosphatase
and tensin homologue on chromosome 10 (PTEN)
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with downstream inhibition of protein kinase B/Akt, a
known prosurvival signaling mediator. Interestingly,
fibroblasts from some patients with IPF are resistant to
the proapoptotic effect of PGE2. These findings reveal
another dimension by which PGE2 may act as an
antifibrotic mediator and contrast with the well-recog-
nized role of PGE2 as a prosurvival mediator in other
cell types.
MATERIALS AND METHODS
Reagents
PGE2, PGD2, the prostacyclin analog iloprost, the thrombox-
ane A2 analog U-4419, and the EP2-specific agonist butaprost
free acid were purchased from Cayman Chemical (Ann
Arbor, MI, USA). The specific caspase 8 inhibitor Z-IETD-
FMK, caspase 9 inhibitor Z-LEHD-FMK, and camptothecin
(CPT) were purchased from Calbiochem (San Diego, CA,
USA). Activating antibody for the Fas (CD95) receptor
(FasL/CD95L/APO-1) was obtained from Millipore (Te-
mecula, CA, USA). Cycloheximide (CHX) was obtained from
Sigma-Aldrich (St. Louis, MO, USA). The EP3-specific agonist
ONO-AE3–248 and the EP4-specific agonist ONO-AE1–329
were generously provided by Ono Pharmaceuticals (Osaka,
Japan). Antibodies for poly-ADP-ribose polymerase (PARP),
Akt, phospho-Akt, PTEN, and survivin were obtained from
Cell Signaling (Danvers, MA, USA); -tubulin was obtained
from Sigma-Aldrich.
Cell culture
Primary normal fetal lung fibroblasts (IMR-90) were obtained
from the Coriell Institute for Medical Research (Camden, NJ,
USA). Fibroblasts from patients with usual interstitial pneu-
monia (UIP), the characteristic histological abnormality of
IPF, were grown from lung explants derived from biopsy
specimens obtained during diagnostic evaluation. Normal
adult control fibroblasts were grown from histologically nor-
mal margins of tissue resected for lung cancer and from cell
lines (CCL201) obtained from American Type Culture Col-
lection (Manassas, VA, USA). All patient-derived cells were
isolated as described previously (31). This study was approved
by the University of Michigan Institutional Review Board, with
all patients providing informed consent. Murine embryonic
PTEN/ and embryonic C57BL/6 wild-type fibroblasts were
isolated as described previously (21). All cells were cultured
in Dulbecco’s modified Eagle medium (Invitrogen, Carlsbad,
CA, USA) with 10% fetal bovine serum (Hyclone, Logan, UT,
USA), and 1% penicillin/streptomycin (Invitrogen). Cells
were studied between passages 5–10.
Annexin V-FITC/propidium iodine (PI) staining
Cells were treated for 24 h in serum-free medium under the
indicated conditions. Detached cells were collected by cen-
trifugation and combined with adherent cells; cells were then
resuspended in Annexin V binding buffer (BD Biosciences,
San Diego, CA, USA). Cells were then incubated with 5 l of
Annexin V-FITC (which binds to phosphatidylserine, present
only on the outer membrane of apoptotic cells) and 5 l of PI
(which binds to DNA) for 15 min at room temperature. Cells
were analyzed and quantitated by flow cytometry.
PARP cleavage
PARP is a target for cleavage by caspases, and increases in
cleaved PARP are indicative of apoptotic cells. Both intact and
cleaved PARP was detected by immunoblotting. Cells
(5105) grown in 6-well plates were treated under the
indicated conditions for 24 h in serum-free medium before
being collected in lysis buffer (phosphate-buffered saline with
1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS).
Any nonadherent cells were centrifuged and combined with
the adherent cells for preparation of lysates. Proteins were
separated by SDS-polyacrylamide gel electrophoresis (PAGE)
and subjected to immunoblot analysis using anti-PARP anti-
body (1:1000).
Single-stranded DNA assay
Denaturation of DNA results in single-stranded DNA (ssDNA)
that is selectively found in condensed chromatin of apoptotic
cells. We measured ssDNA by immunoassay, as described
previously (32). Cells (5103) grown in 96-well plates were
treated for 24 h in serum-free medium. DNA was then
denatured with formamide, and ssDNA was detected by a
monoclonal antibody (Chemicon, Billerica, MA, USA). After
washing, the bound antibody was detected by ABTS chro-
mophore (Calbiochem) and quantitated on an absorbance
plate reader, with values corrected for cell count.
Caspase 3, 8, and 9 assays
Caspase 3 activity was measured in cell lysates using the
Caspase-3 Fluorometric Assay Kit (Assay Designs, Ann Arbor,
MI, USA), according to manufacturer’s protocol. All cells
were treated under the indicated condition in serum-free
medium for 24 h before being collected for assay. Caspase 8
and 9 activities were measured in lysates using the Caspase 8
and Caspase 9 Fluorometric Assay Kits (R&D Systems, Minne-
apolis, MN, USA), performed according to manufacturer’s
protocol. All values were normalized for protein concentra-
tion.
PTEN siRNA
IMR-90 cells were transfected using Lipofectamine LTX (In-
vitrogen) with either 100 nM of PTEN siRNA (Cell Signaling)
or nonspecific scrambled siRNA (Cell Signaling). Cells were
studied at 48 h after transfection.
Immunoblotting
Proteins from cell lysates were separated by SDS-PAGE and
transferred to nitrocellulose membranes for immunoblotting, as
described previously (33). Antibodies for Akt, phospho-Akt,
PTEN, survivin, and -tubulin were used at 1:1000; antibody for
Fas receptor was used at 1:500. Bound primary antibodies were
visualized with appropriate secondary antibody conjugated to
horseradish peroxidase and developed with enhanced chemi-
luminescence reagent (GE Healthcare, Piscataway, NJ, USA).
Densitometric analysis was performed using Scion Image
(U.S. National Institutes of Health, Bethesda, MD, USA).
Data analysis
Statistical analysis was performed using either ANOVA or
Student’s t test, as appropriate, using GraphPad Prism 5.0
(GraphPad Software, San Diego, CA, USA). A value of P 
0.05 was considered statistically significant.
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RESULTS
PGE2 elicits a dose-dependent increase in fibroblast
apoptosis
To determine the effects of PGE2 on lung fibroblast
survival, we treated IMR-90 cells for 24 h with increasing
doses of PGE2 (10–1000 nM) and measured cellular
apoptosis by annexin V staining, caspase 3 activity,
cleavage of PARP, and ssDNA levels (Fig. 1). In all
assays, PGE2 elicited a dose-dependent increase in
apoptosis (EC5050 nM), with maximal effects seen at
500–1000 nM. Vehicle control consisting of medium
with 0.01% dimethyl sulfoxide (which corresponds to
the amount of dimethyl sulfoxide in the 1000 nM PGE2
treatment condition) elicited no significant increase in
apoptosis over that observed in untreated cells. PGE2
treatment resulted in an increase in annexin V/PI
cells (early apoptosis), but no change in annexin
V/PI (late apoptosis/necrosis) or annexin V/PI
cells (necrosis).
We next examined the effects of PGE2 on fibroblast
survival in the presence of another apoptotic stimulus.
FasL plus cycloheximide have been shown to induce
fibroblast apoptosis, and impaired susceptibility to
FasL-induced apoptosis has been observed in cells from
patients with pulmonary fibrosis (10, 11). Combined
treatment with PGE2 and FasL/cycloheximide led to
more apoptosis than did either alone (Fig. 2). This
finding shows that PGE2 augments fibroblast apopto-
sis in the presence of another known apoptotic
stimulus.
PGE2 induces apoptosis via EP2-EP4 receptor
signaling
PGE2 can signal through 4 distinct G-protein-coupled
EP receptors (EP1–4). In lung fibroblasts, the Gs-
coupled EP2 is the most abundantly expressed (33) and
mediates the signaling necessary for inhibition of col-
lagen synthesis, cell proliferation (33), and fibroblast
migration (21). To determine which EP receptors are
responsible for PGE2-induced apoptosis, we treated
cells with specific EP2, EP3, and EP4 agonists. An
increase in apoptosis was observed with agonists for
both of the Gs-coupled EP2 and EP4 receptors but not
with the Gi-coupled EP3 agonist (Fig. 3). Interestingly,
among other prostanoids tested, PGD2, which is pro-
duced predominantly by mast cells and signals through
the Gs-coupled DP receptor, was also able to elicit
apoptosis. A stable analog of thromboxane A2, which
signals through the Gi-coupled TP receptor, did not.
Iloprost, a stable analog of prostacyclin, which signals
through the Gs-coupled IP receptor, elicited a degree
of apoptosis that was slightly greater than untreated
control cells. (Supplemental Fig. 1).
Both intrinsic and extrinsic pathways mediate PGE2-
induced apoptosis
The development of apoptosis can proceed through
various pathways (34). The intrinsic, or mitochondrial,
pathway is activated under conditions of metabolic
stress; cytochrome c is released from the mitochondria
Figure 1. PGE2 dose-dependently increases fibroblast apoptosis. IMR-90 fibroblasts
were treated for 24 h with varying concentrations of PGE2 and apoptosis was
measured by annexin V/PI staining (n	3) (A), caspase 3 activity (n	3) (B),
cleavage of PARP (n	4) (C), and ssDNA levels (n	3) (D), as described in
Materials and Methods. *P  0.05 vs. untreated cells.
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with activation of the apoptosome complex containing
caspase 9, which leads to further cleavage of down-
stream effector caspases 3, 6, and 7 (35). The extrinsic,
or death receptor, pathway involves the binding of
extracellular signals (i.e., FasL, TNF-) to death recep-
tors (i.e., Fas), which, in turn, triggers the formation of
the death-induced signaling complex, which leads to
activation of caspase 8 (36, 37); activated caspase 8
further cleaves downstream effector caspases.
To determine which pathway might be responsible
for PGE2-induced apoptosis, we first measured the
activities of both caspases 8 and 9 in cells treated with
PGE2. PGE2 induced a 25 
 7.8% increase in caspase 8
activity and a 48 
 10.9% increase in caspase 9 activity
(P0.05 for both). Furthermore, both the caspase 8
inhibitor Z-IETD-FMK and the caspase 9 inhibitor
Z-LEHD-FMK (Fig. 4A, B), at concentrations used in
other studies (38, 39), independently inhibited PGE2-
induced apoptosis. These findings suggest that PGE2
requires activation of both caspase 8 and caspase 9 to
induce fibroblast apoptosis.
PTEN is required for PGE2-induced apoptosis
PTEN is a lipid phosphatase that antagonizes the phospha-
tidylinositol-3-kinase (PI3K) pathway by dephosphorylating
phosphatidylinositol 3,4,5-trisphosphate (PIP3) (40).
PIP3 is a lipid mediator that recruits and activates
proteins with pleckstrin homology domains such as Akt,
which has been shown to be an important prosurvival
mediator (41) that can inhibit both the intrinsic (42)
and extrinsic (43) apoptotic pathways. Previous work
has shown that PGE2 activation of PTEN, with subse-
quent loss of Akt activity, is responsible for PGE2
inhibition of fibroblast migration (21). We sought to
determine whether this same pathway is responsible for
PGE2-mediated apoptosis of fibroblasts.
We first sought to examine the apoptotic effects of
PGE2 in murine fibroblasts from embryonic PTEN
/
mice (PTEN/ mice do not survive to gestation). As
expected, PGE2 was unable to decrease Akt phosphor-
ylation in PTEN/ fibroblasts, in contrast to its ability
to do so in wild-type embryonic fibroblasts (Fig. 5A).
Unlike control wild-type embryonic fibroblasts, fibro-
blasts from PTEN/ mice were likewise not suscepti-
ble to apoptosis by PGE2 (Fig. 5B). However, these cells
were still susceptible to the alternative inducer of
apoptosis, the topoisomerase inhibitor CPT. These
findings suggest that activation of PTEN and subse-
quent inhibition of Akt is necessary for PGE2 to induce
apoptosis.
To confirm the importance of PTEN in PGE2-in-
duced apoptosis, we also silenced PTEN expression in
IMR-90 cells using siRNA (Fig. 6A). As with cells from
PTEN/ mice, fibroblasts treated with PTEN siRNA
similarly failed to undergo apoptosis in response to
PGE2 but were susceptible to cell death evoked by CPT
(Fig. 6B). These findings show that PTEN is critical to
PGE2-induced apoptosis in fibroblasts.
PGE2 decreases survivin expression and increases Fas
receptor expression
Akt activates multiple downstream pathways that are
responsible for its prosurvival effects, including the
induction of multiple antiapoptotic genes (41). These
include the inhibitors of apoptosis proteins (IAPs)
which directly inhibit caspases. Among the IAPs, sur-
Figure 2. PGE2 potentiates FasL-induced apoptosis of fibro-
blasts. IMR-90 fibroblasts were treated in the presence or
absence of PGE2 (0.1 M) and FasL (100 ng/ml) plus CHX
(0.5 g/ml) for 24 h, and cellular apoptosis was measured by
annexin V/PI staining (n	3). Results are expressed as the
percentage of annexin V/PI (early apoptosis) cells. *P 
0.05.
Figure 3. PGE2 elicits apoptosis via EP2/EP4 signaling.
IMR-90 cells were treated for 24 h with PGE2 (500 nM), the
EP2-specific agonist butaprost free acid (BFA; 500 nM), the
EP3-specific agonist ONO-AE3–248 (100 nM), or the EP4-
specific agonist ONO-AE1–329 (100 nM), and apoptosis was
measured by cleavage of PARP. Top panel: representative
blot. Bottom panel: densitometric analysis of cleaved PARP
relative to -tubulin (n	3). *P  0.05 vs. untreated control.
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vivin has been shown to be important in lung cancer
(44) and colorectal cancer cells (45). Cancer cells
exhibit increased survivin expression, which directly
inhibits caspases (46). It is down-regulated by Akt
signaling (47) and has been shown to be up-regulated
by PGE2 in lung cancer cells (48). Because survivin is a
target of both Akt and PGE2 signaling, we examined its
expression in fibroblasts treated with PGE2. Survivin
expression was dose-dependently inhibited by PGE2
(Fig. 7A), which is in contrast to the action of this
prostanoid observed in cancer cells (48, 49).
Because Akt has also been shown to protect cells
from the extrinsic apoptotic pathway (50) and because
we found that PGE2 potentiates FasL-induced apopto-
sis, we also examined the effects of PGE2 on expression
of the Fas receptor. PGE2 dose-dependently increased
Fas receptor expression (Fig. 7B). Together, these data
show that PGE2 can affect expression of multiple tar-
gets that all enhance fibroblast apoptosis.
Variable resistance to PGE2-induced apoptosis is
observed in fibroblasts from patients with UIP
We examined the apoptotic response to PGE2 of fibro-
blasts from patients with UIP/IPF. Previous work in our
Figure 4. PGE2 promotes fibroblast apoptosis via both
caspases 8 and 9. A) IMR-90 fibroblasts were treated with
PGE2 (0.5 M) in the presence or absence of the caspase 8
inhibitor Z-IETD-FMK (25 M) or the caspase 9 inhibitor
Z-LEHD-FMK (25 M) for 24 h. Caspase 3 activity was
measured as described in Materials and Methods; data are
expressed as a percentage of activity relative to the no-PGE2
control (n	4). *P  0.05. B) IMR-90 fibroblasts were treated
with PGE2 (0.5 M), Z-IETD-FMK (25 M), and/or Z-LEHD-
FMK (25 M) for 24 h. Lysates were immunoblotted for
cleaved PARP. Top panel: representative immunoblot. Bot-
tom panel: densitometry of cleaved PARP normalized to
-tubulin (n	3).
Figure 5. Diminished capacity for PGE2-induced apoptosis in
PTEN/ fibroblasts. PTEN/ and wild-type (wt) murine
embryonic fibroblasts were treated for 24 h with PGE2 at the
indicated concentrations. Phosphorylated Akt (A) and
cleaved PARP (B) were assayed by immunoblot analysis. Top
panels: representative immunoblots. Bottom panels: relative
densitometry normalized to untreated controls (wt, n	3;
PTEN/, n	4). *P  0.05.
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laboratory has shown that in many of these patient-
derived cell lines, fibroblasts are resistant to the sup-
pressive effects of PGE2 on collagen expression and cell
proliferation (16). Each of the three nonfibrotic fibro-
blast lines exhibited dose-dependent apoptosis in re-
sponse to PGE2. By comparison, the group of 8 lines of
UIP fibroblasts exhibited a relative degree of resistance
to PGE2-elicited apoptosis (Fig. 8A). However, when
the responses of individual UIP lines were examined, 3
lines exhibited dose-related apoptosis to PGE2, while 5
lines were mainly resistant. This variable response
among different UIP fibroblast lines is consistent with
the variable inhibitory effects of PGE2 on collagen
expression and cell proliferation, which we observed
previously (16).
Previous studies have also shown that UIP fibroblasts
are resistant to FasL-induced apoptosis (10, 11), and
data in Fig. 8B support this conclusion. In control cells,
PGE2 potentiated the proapoptotic effects of FasL/
cycloheximide; although this appeared to be the case in
the UIP cell lines as well, the degree of potentiation was
less than observed in normal cell lines (Fig. 8B). A
summary of PGE2-mediated apoptotic signaling is
shown in Fig. 9.
DISCUSSION
PGE2 has been shown to be antiapoptotic in multiple
cell types, including normal epithelial cells (24, 25),
cancer cells (26, 27), T cells (28, 29), and adipocytes
(30). Despite the well-known contribution of fibroblast
survival to the accumulation of this key mesenchymal
cell in tissue fibrosis, there are few studies that have
addressed the effects of this prostanoid on fibroblast
survival. Our studies demonstrate for the first time that
in contrast to its predominant antiapoptotic effect in
other cell types, PGE2 promotes apoptosis of lung
fibroblasts. These findings provide a novel mechanism
by which PGE2 may mediate antifibrotic effects.
The pathobiology of pulmonary fibrosis is character-
ized by an increase in epithelial cell apoptosis (2–4)
and a decrease in fibroblast apoptosis (5–8). The
importance of TGF- as a profibrotic mediator derives
in part from its ability to promote each of these
opposing effects—a phenomenon that has been
termed the “apoptosis paradox” (7, 51). That PGE2 acts
as an antiapoptotic signal in epithelial cells (24, 25) but
as a proapoptotic signal in fibroblasts therefore signi-
fies another such apoptosis paradox and emphasizes
the pleiotropic antifibrotic potential of PGE2. The fact
that impaired synthesis of PGE2 in pulmonary fibrosis
(12–14) would be expected to promote fibroblast sur-
vival may explain the persistent fibrogenesis observed
in this disease.
Our studies employing both RNA silencing and gene
Figure 6. PTEN silencing diminishes PGE2-induced apoptosis
in fibroblasts. A) PTEN expression was assayed by immuno-
blot in cells treated with control or PTEN siRNA for 48 h. Top
panel: representative blot. Bottom panel: mean densitometric
data (n	4). *P  0.05. B) PTEN siRNA- and control siRNA-
treated cells were exposed to PGE2 (0.1 M) for 24 h, and
cleaved PARP was assayed by immunoblot. Top panel: repre-
sentative blot. Bottom panel: densitometry of cleaved PARP/
-tubulin (n	3). CPT (2 g/ml) was used as a positive
control. *P  0.05 vs. no-PGE2 treatment.
Figure 7. PGE2 modulates fibroblast expression of survivin
and Fas receptor. IMR-90 fibroblasts were treated for 24 h
with the indicated concentrations of PGE2, and survivin
expression (n	3) (A) and Fas receptor expression (n	3) (B)
were determined by immunoblot analysis. *P  0.05 vs.
no-PGE2 treatment.
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deletion indicate that PGE2-induced fibroblast apopto-
sis is dependent on PTEN activation; this results in
down-regulation of Akt, a molecule that has been
shown to be important in prosurvival signaling (41).
The contrasting actions of PGE2 in fibroblasts vs. epi-
thelial cells may be explained by differences in PTEN/
Akt signaling, since we have shown that PGE2 activates
PTEN and inhibits Akt (21) in the former, while it
activates Akt in epithelial (24) and cancer cells (52).
Although the measured increases in caspase 8 and
caspase 9 activities were modest, both appear to partic-
ipate in PGE2-induced apoptosis on the basis of data
using selective inhibitors. The importance of both the
intrinsic (as reflected by the role for caspase 9) and
extrinsic (as reflected by the role for caspase 8) apo-
ptosis pathways is not surprising, given their recognized
capacity for crosstalk (53).
We furthermore show for the first time that PGE2
inhibits expression of survivin. This once again con-
trasts with findings in other cell types, in which PGE2
was shown to increase survivin expression in cancer
cells (48, 49), thereby contributing to its role in pro-
moting oncogenesis. We also found that PGE2 increases
expression of Fas. These findings contrast with reports
of PGE2 decreasing FasL expression in T cells, thereby
preventing T-cell activation-induced cell death (29).
This contrasting action on the Fas/FasL pathway fur-
ther illustrates that actions of PGE2 are cell-type depen-
dent.
Previous studies have shown that a chemical inhibitor
of Akt, LY294002, does not increase baseline fibroblast
apoptosis (32), suggesting that increased PTEN activity/
decreased Akt activity by PGE2 may be necessary, but
not sufficient, for PGE2-induced apoptosis. Rather, this
may require the contributions of additional proapop-
totic pathways, including increased Fas expression and
decreased survivin expression. Indeed, increased Fas
expression could explain our finding that PGE2 poten-
tiates apoptosis elicited by FasL plus cycloheximide.
The possible interrelationship among increased Fas
expression, decreased survivin expression, and PTEN/
Akt signaling requires further investigation, and the
relative contributions of EP2 and EP4 receptor signal-
ing to these three mechanisms remain to be deter-
mined. However, the observation that PGE2 modulates
multiple determinants of apoptosis in lung fibroblasts
may explain its ability to activate both intrinsic and
Figure 8. PGE2-induced apoptosis in adult control and UIP fibroblasts. A) Fibroblasts from the lungs of patients with UIP (n	8,
white bars) and nonfibrotic controls (n	3, black bars) were treated with PGE2 for 24 h, and apoptosis was measured by annexin
V/PI staining, with results expressed as the percentage of annexin V/PI (early apoptosis) cells. Responses of individual UIP
lines are displayed at right, segregated within responsive and unresponsive groups. B) UIP (n	3) and nonfibrotic control (n	4)
fibroblasts were treated with PGE2 (0.1 M) 
 FasL (100 ng/ml)  CHX (0.5 g/ml) for 24 h. Cells were stained for annexin
V and PI; percentage of annexin V/PI cells is shown.
Figure 9. Schema of PGE2-induced apoptosis in lung fibro-
blasts. PGE2, synthesized by the cyclooxygenase (COX) path-
way, induces apoptosis by increasing PTEN activity and de-
creasing Akt activity. PGE2 also decreases survivin and
increases Fas expression in lung fibroblasts. PGE2-induced
apoptosis is mediated by ligation of the EP2 and EP4 recep-
tors; relative contributions of EP2 and EP4 signaling to the 3
apoptosis pathways remain to be determined.
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extrinsic pathways, as well as its potential to influence
apoptosis in diverse biological contexts.
PGE2 synthesized by neighboring epithelial cells or
fibroblasts themselves may act as a paracrine or auto-
crine brake to limit excessive fibroblast accumulation
under normal homeostatic conditions. Since PGE2 en-
hanced FasL-induced apoptosis even in UIP fibroblasts,
which were previously shown to be resistant to FasL
signaling (10, 11), it may play an important role in
sensitizing cells to apoptosis. Thus, the modest magni-
tude of PGE2-induced apoptosis does not diminish its
biological importance, and the actions of PGE2 may
help potentiate other apoptosis-targeted therapies.
A previous study has shown that PGE2 protects
against fibroblast apoptosis in the presence of cigarette
smoke extract (54). These experiments were per-
formed in cells treated for only 6 h, and the effects of
PGE2 alone were not tested. Our findings instead
examined the effects of PGE2 both alone and with the
addition of FasL, employing later time points that may
be more relevant to the kinetics of apoptosis. Neverthe-
less, the seemingly disparate findings between the two
experimental models may also point to the pleiotropic
actions of PGE2 in the presence of differing apoptotic
signals.
Studies in UIP fibroblasts demonstrated that many,
but not all, cell lines exhibited resistance to the pro-
apoptotic effects of PGE2. This mirrored our previous
findings in which some but not all UIP fibroblast lines
exhibited resistance to PGE2-mediated inhibition of
collagen synthesis and cell proliferation (14). Multiple
mechanisms (diminished EP2 expression, diminished
protein kinase A expression, and activity) accounted for
resistance to PGE2 inhibition of collagen synthesis and
cell proliferation (14). Given that PGE2-induced apo-
ptosis proceeds via EP2/EP4 receptor activation, it is
likely that apoptosis resistance in UIP cells reflects
these same mechanisms responsible for resistance to
PGE2 inhibition of collagen synthesis and cell prolifer-
ation. Interestingly, decreased PTEN expression has
also been described in fibroblasts from some UIP
patients (55), possibly also contributing to their resis-
tance to apoptosis.
Although our studies address PGE2-mediated fibro-
blast apoptosis in vitro, the in vivo relevance of this
phenomenon remains to be determined. However, it is
of interest that the cyclooxygenase inhibitor indometh-
acin was shown to worsen bleomycin-induced fibrosis in
mice (56). As PGE2 is the major cyclooxygenase-derived
prostanoid produced by both alveolar epithelial cells
(57) and fibroblasts (57), it has the capability to elicit
fibroblast apoptosis in both a paracrine and autocrine
fashion. Although we found that PGD2 likewise pos-
sesses this capability, its relevance in the setting of
parenchymal fibrogenesis is less apparent.
CONCLUSIONS
As opposed to normal and malignant epithelial cells,
for which PGE2 is antiapoptotic, we show that PGE2
promotes apoptosis of lung fibroblasts, and that this
involves enhanced PTEN signaling and decreased
Akt activation. PGE2 also decreased survivin and
increased Fas receptor expression. A resistance to
PGE2-induced apoptosis was observed in some UIP
cells, which could be overcome with the combination
of FasL and cycloheximide. Although PGE2 has pre-
viously been demonstrated to inhibit the activation of
diverse fibrogenic functions in lung fibroblasts, its
ability to promote apoptosis offers a potential oppor-
tunity not merely to prevent progression of pulmo-
nary fibrosis but to intervene in and potentially
reverse established disease.
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